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A B S T R A C T
Ubiquitylation is an important posttranslational protein modiﬁcation that is involved in many cellular events.
Immunopuriﬁcation of peptides containing a K-ε-diglycine (diGly) remnant as a mark of ubiquitylation com-
bined with mass spectrometric detection has resulted in an explosion of the number of identiﬁed ubiquitylation
sites. Here, we present several signiﬁcant improvements to this workﬂow, including fast, oﬄine and crude high
pH reverse-phase fractionation of tryptic peptides into only three fractions with simultaneous desalting prior to
immunopuriﬁcation and better control of the peptide fragmentation settings in the Orbitrap HCD cell. In ad-
dition, more eﬃcient sample cleanup using a ﬁlter plug to retain the antibody beads results in a higher speci-
ﬁcity for diGly peptides and less non-speciﬁc binding. These relatively simple modiﬁcations of the protocol result
in the routine detection of over 23,000 diGly peptides from HeLa cells upon proteasome inhibition. The eﬃcacy
of this strategy is shown for lysates of both non-labeled and SILAC labeled cell lines. Furthermore, we demon-
strate that this strategy is useful for the in-depth analysis of the endogenous, unstimulated ubiquitinome of in
vivo samples such as mouse brain tissue. This study presents a valuable addition to the toolbox for ubiquitylation
site analysis to uncover the deep ubiquitinome.
Signiﬁcance: A K-ε-diglycine (diGly) mark on peptides after tryptic digestion of proteins indicates a site of
ubiquitylation, a posttranslational modiﬁcation involved in a wide range of cellular processes. Here, we report
several improvements to methods for the isolation and detection of diGly peptides from complex biological
mixtures such as cell lysates and brain tissue. This adapted method is robust, reproducible and outperforms
previously published methods in terms of number of modiﬁed peptide identiﬁcations from a single sample. In-
depth analysis of the ubiquitinome using mass spectrometry will lead to a better understanding of the roles of
protein ubiquitylation in cellular events.
1. Introduction
The conjugation of the 8.5 kD protein ubiquitin to target proteins to
mark them for proteasomal degradation is one of the key processes in
cellular proteostasis. In this process the C-terminal carboxyl group of
ubiquitin forms a covalent isopeptide bond with the ε-amino group of a
lysine residue of the target protein. Ubiquitin is attached in a signaling
cascade in which three enzyme types play a role, i.e. E1, E2 and E3
ubiquitin ligases [1,2]. Also, the ubiquitin moiety can be attached to
another ubiquitin module, leading to the formation of branched poly-
ubiquitin structures [1,3].
Although the initial discovery of ubiquitin was related to its role in
mediating proteasomal degradation, it has become clear that protein
mono- and polyubiquitylation is also involved in many proteasome-
independent processes such as lysosomal degradation, DNA repair sig-
naling, coordinating the cellular localization of proteins, activating and
inactivating proteins and modulating protein-protein interactions [4].
The observation that proteins involved in ubiquitin signaling are often
mutated in diseases such as cancer and neurodegenerative disorders
illustrates the importance of ubiquitin in various key cellular processes
[4,5].
Mass spectrometry has become the method of choice for the analysis
of the cellular proteome over the past decade. Near complete proteomes
representing thousands of diﬀerent proteins from any biological source
material can now be identiﬁed within a reasonable amount of time.
While a mass spectrometric analysis is qualitative by nature, the use of
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metabolic or chemical labeling can be used to add a robust quantiﬁ-
cation element to the analysis. Also, mass spectrometry is an indis-
pensable tool for the analysis of protein posttranslational modiﬁcations
(PTMs), ranging from small chemical moieties such as phosphorylation
to complex glycan structures and small proteins such as ubiquitin and
SUMO, with diverse biological functions.
Due to the nature of the mass spectrometric analysis, enrichment
steps are necessary when measuring modiﬁed proteins or proteolytic
peptides in order to cope with the generally relatively low stoichio-
metry of modiﬁed peptides compared to their non-modiﬁed counter-
parts. A range of speciﬁc methods have been developed to enhance the
analysis of various PTMs such as phosphorylation, methylation, acet-
ylation, ubiquitylation, etc.
Due to the multifaceted and important roles of ubiquitin, there is a
great interest in the development of analytical methods for the (mass
spectrometric) detection of protein ubiquitylation [6]. The use of mass
spectrometry for the analysis of protein ubiquitylation has resulted in
an explosion of the number of identiﬁed ubiquitylation sites in human,
murine, Drosophila and yeast proteins over the past ﬁve years [7–12]. A
major leap forward was presented by the development of an enrichment
strategy based on immunoprecipitation using highly speciﬁc antibodies
against the K-ε-GG (also referred to simply as diglycine or diGly)
remnant motif that is produced upon tryptic digestion of ubiquitylated
proteins [13,14].
This highly eﬀective enrichment strategy has been used to in-
vestigate endogenous ubiquitylation sites in human cell lines [14],
whether or not including fractionation of the immunoenriched peptides
using isoelectric focusing or strong cation exchange (SCX) chromato-
graphy [10]. Adaptations to such protocols have been described by
Udeshi and coworkers, who included fractionation of digested lysates
based on SCX chromatography prior to immunoaﬃnity enrichment in a
study to the eﬀect of proteasome inhibition by MG132 and deubiqui-
tinase inhibition by PR619 on ubiquitination sites in human Jurkat cells
[11] and several improvements of this method, including optimized
antibody and peptide input requirements, antibody cross-linking and
improvement of basic reverse-phase oﬄine fractionation prior to en-
richment [15]. Recently, a method was described to quantitatively
compare the ubiquitinomes from mouse tissue in a multiplexed manner
using isobaric tagging with TMT [16].
Here, we describe a modiﬁed workﬂow to enrich for and detect
diGly peptides originating from ubiquitylated proteins using im-
munopuriﬁcation. Using a combination of several relatively simple
modiﬁcations in the sample preparation and mass spectrometric de-
tection protocols, we now routinely detect over 23,000 diGly modiﬁed
peptides in a single sample of cells treated with proteasome inhibitors.
We show the eﬃcacy of this strategy for lysates from both non-labeled
Fig. 1. Overview of the experimental approach. Samples are prepared, trypsinized and fractionated into three fractions using reverse-phase chromatography with high pH elution. One
batch of commercial α-diGly peptide antibody beads is split into six equal fractions and the three peptide fractions are then loaded on three of the beads fractions. The diGly peptides are
immunopuriﬁed, eluted and collected, and the ﬂowthrough is subsequently transferred to the three remaining fresh beads fractions. The collected diGly peptides are analyzed by mass
spectrometry on a Lumos Orbitrap mass spectrometer in a two-tier system consisting of one cycle in which the most intense peaks are ﬁrst selected for peptide fragmentation and the next
cycle in which the least intense peaks are selected ﬁrst. The complete set of nLC-MS/MS runs are then analyzed using MaxQuant.
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and metabolically labeled (SILAC) mammalian cells. Furthermore, we
demonstrate that this optimized strategy is also useful for the in-depth
identiﬁcation of the endogenous, unstimulated ubiquitinome of in vivo
samples such as mouse brain tissue. As such, this study presents a
valuable addition to the toolbox of the ubiquitylation site analysis for
the identiﬁcation of the deep ubiquitinome.
2. Material and methods
2.1. Sample preparation
Human cervical cancer cells (HeLa) and human osteosarcoma cells
(U2OS) were grown in Dulbecco's Minimal Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS; heat inactivated,
Gibco) and 100 units/ml penicillin/streptomycin. For SILAC experi-
ments, cells were cultured in specially formulated DMEM (Thermo)
lacking conventional Arginine and Lysine, supplemented with 10%
dialyzed FBS (Sigma), 100 units/ml penicillin/streptomycin and glu-
tamax (Gibco). SILAC cells were labeled with either conventional
Lysine and Arginine (Sigma; referred to as ‘Light’), Lysine-4 (4,4,5,5-D4)
and Arginine-6 (13C6) or Lysine-8 (13C6;15N2) and Arginine-10
(13C6;15N4) (Cambridge Isotope Laboratories; referred to as ‘Medium’ or
‘Heavy’, respectively). Cells were grown in this medium for at least 6
doublings before expansion and treatment.
After treatment with 10 μM Bortezomib (UBPbio) or an equivalent
volume of DMSO as a mock treatment for 8 h, cells were washed with
PBS, dissociated using 1% trypsin/EDTA and pelleted. Cell lysis was
performed in 50 mM Tris-HCl (pH 8.2) with 0.5% sodium deoxycholate
(DOC). Brieﬂy, cells were incubated with the buﬀer and then boiled and
sonicated for 10 min using a Bioruptor (Diagenode). Protein quantita-
tion was performed using the colorimetric absorbance BCA protein
assay kit (Thermo). Proteins were reduced using 5 mM 1,4-dithio-
threitol for 30 min at 50 °C and subsequently alkylated using 10 mM
iodoacetamide for 15 min in the dark. Proteins were ﬁrst digested for
4 h with Lys-C (Wako Pure Chemicals; 1:200 enzyme:substrate ratio)
and then overnight with trypsin (Thermo; 1:50 enzyme:substrate ratio)
at 30 °C. Detergent was then removed by adding triﬂuoroacetic acid
(TFA) to 0.5% and precipitated detergent was spun down at 10,000g for
10 min.
Mouse brain tissues were lysed using phase transfer surfactant (PTS;
composed of 100 mM Tris-HCl (pH 8.5), 12 mM sodium DOC and
12 mM sodium N-lauroylsarcosinate) [17]. Brieﬂy, tissues were in-
cubated with the buﬀer and then boiled and sonicated for 10 min using
a Bioruptor (Diagenode). Protein quantitation and digestion was per-
formed as described above.
Peptide fractionation using high pH reverse-phase chromatography
was performed using polymeric PLRP-S (300 Å, 50 μm, Agilent
Technologies, part #PL1412-2K01) stationary phase material loaded
into an empty Sep-Pak column cartridge (Waters). The stationary phase
bed size was adjusted to the amount of protein digest that was to be
fractionated. For 10 mg protein digest a 6 cm3 Sep-Pak column car-
tridge ﬁlled with 0.5 g of stationary phase was used, resulting in a
protein digest: stationary phase ratio of 1:50. The sample was loaded
onto the column and washed with 10 column volumes of 0.1% TFA and
10 column volumes of milliQ H2O. Next, peptides were eluted into three
fractions with 10 column volumes of 10 mM ammonium formate so-
lution (pH 10) and 7%, 13.5% and 50% acetonitrile (AcN), respectively.
Fractions and ﬂowthrough were subsequently dried to completeness by
lyophilization.
For immunoprecipitation of diGly peptides, ubiquitin remnant motif
(K-ε-GG) antibodies coupled to beads (PTMscan, Cell Signaling
Technologies) were used. Each standard batch of beads was washed
twice with PBS and then split into six fractions. The peptide fractions
were dissolved in 1.4 ml IAP buﬀer (50 mM MOPS, 10 mM sodium
phosphate and 50 mM NaCl, pH 7.2) and debris was spun down. The
supernatant of the three fractions was incubated with beads for 2 h at
4 °C on a rotator unit. Subsequently, the supernatant was incubated
again with the remaining bead fractions for 2 h at 4 °C. The supernatant
was stored for further global proteome (GP) analysis.
Beads were transferred into a P200 pipette tip equipped with a GF/F
Fig. 2. Numbers of diGly peptides detected for each of the three improvement steps. The
amount of unique diGly peptides per variable parameter in each improvement step is
shown in dark blue; the total number of diGly peptides including those detected in
multiple fractions, in both 1st and 2nd incubation or in both peak intensity priority
fragmentation regimes is shown in light blue. Unique peptides are deﬁned as those that do
not overlap between the diﬀerent parameters of each improvement step (i.e., fractions,
1st or 2nd incubation, fragmentation regimes). Bars indicate standard deviation.
Fig. 3. DiGly peptides detected in three biological replicates of Bortezomib treated cells
showing the amount of overlap between the runs.
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ﬁlter plug (Whatman part #1825-021) to retain the beads. The beads
were then washed 3 times with 200 μl of ice cold IAP buﬀer and sub-
sequently 5 times with 200 μl of ice cold milliQ H2O and peptides were
eluted using 2 cycles of 50 μl 0.15% TFA. Finally, peptides were de-
salted using a C18 stage tip and dried to completeness using vacuum
centrifugation.
2.2. NanoLC-MS
Mass spectra were acquired on an Oribtrap Tribrid Lumos mass
spectrometer (Thermo) coupled to an EASY-nLC 1200 system (Thermo).
Peptides were separated on an in-house packed 75 μM inner diameter
column containing 50 cm Waters CSH130 resin (3.5 μm, 130 Å, Waters)
with a gradient consisting of 2–28% (AcN, 0.1% FA) over 120 min at
300 nl/min. The column was kept at 50 °C in a NanoLC oven - MPI
design (MS Wil GmbH). For all experiments, the instrument was oper-
ated in the data-dependent acquisition (DDA) mode. MS1 spectra were
collected at a resolution of 120,000 with an automated gain control
(AGC) target of 4E5 and a max injection time of 50 ms. The Thermo
Tune software was set in such a way that in “highest intensity ﬁrst”
mode ﬁrst the most intense ion was selected for MS/MS, then the
second highest, etc. using the top speed method with a cycle time of 3 s.
In contrast, in “lowest intensity ﬁrst” mode the least intense ion was
selected ﬁrst, then the second lowest, etc. This option was discontinued
from Tune version 2.1.1565.23 onward. Precursors were ﬁltered ac-
cording to charge state (2–7z), and monoisotopic peak assignment.
Previously interrogated precursors were dynamically excluded for 60 s.
Peptide precursors were isolated with a quadrupole mass ﬁlter set to a
width of 1.6 Th. Ion trap MS2 spectra were collected at an AGC of 7E3,
max injection time of 50 ms and HCD collision energy of 30%.
2.3. Data analysis
RAW ﬁles were analyzed using the MaxQuant software suite (ver-
sion 1.5.4.1 or 1.5.6.0) [18]. Default search settings were selected with
a few adaptations. Brieﬂy, the enzyme speciﬁcity was set to trypsin,
with the maximum number of missed cleavages raised to three. Lysine
with a diGly remnant, oxidation of methionine and N-terminal acet-
ylation were set as variable modiﬁcations. Carbamidomethylation of
cysteine was set as a ﬁxed modiﬁcation. Searches were performed
against a Uniprot fasta ﬁle composed of all Homo sapiens protein se-
quences (version June 2016) for the HeLa and U2OS experiments or all
Mus musculus protein sequences (version July 2017) for the mouse brain
experiments, combined with decoy and standard contaminant data-
bases. The false discovery rate was set to 1%. The minimum score for
diGly peptides was set to 40 (default); peptides identiﬁed with a C-
terminal diGly modiﬁed lysine residue were excluded from further
analysis. For the quantitative analysis of SILAC experiment ﬁles
Fig. 4. A) Comparison of diGly peptides detected using increasing
amounts of total protein input material. The ratio of numbers of
diGly peptides to numbers of all peptides was determined to assess
the enrichment eﬃciency, B) Plots of diGly peptide mass spectral
intensities versus peptide masses showing the overlap between and
unique identiﬁcations of the experiments with 4, 10 or 40 mg total
protein input material.
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(multiplicity = 2) the minimum ratio count was set to 1. For assess-
ment of the total number of diGly peptides identiﬁed from the SILAC
experiments, searches were performed with the multiplicity reduced to
1, including the variable modiﬁcations Lysine-4 and Lysine-8 with their
diGly modiﬁed counterparts and Arginine-6 and Arginine-10. Down-
stream analyses were performed with the Perseus package and with in-
house developed software. Sequences from both PhosphoSitePlus and
MaxQuant were converted to tables in a relational database (Post-
greSQL) and manipulated as the respective sequence formats are
somewhat diﬀerent. Subsequently, they were (SQL) queried for over-
lapping sequences.
3. Results & discussion
We set out to develop and improve protocols for sample preparation
and mass spectrometric detection of protein ubiquitylation sites in
proteins from mammalian cultured cells. In order to boost protein
ubiquitylation in cultured cells the chymotrypsin β5 proteasomal in-
hibitor Bortezomib was added for a few hours prior to cell lysis, protein
isolation and subsequently tryptic digestion and mass spectrometric
detection. Ubiquitylated proteins leave a diGly remnant on the ubi-
quitylated lysine when digested with trypsin and the mass diﬀerence
caused by this motif can be used to unambiguously recognize ubiqui-
tylation sites. Here, we describe a strategy that combines several im-
provements to state-of-the-art methods for the characterization of diGly
peptides by nanoﬂow-liquid chromatography-mass spectrometry (nLC-
MS/MS) which is outlined in Fig. 1. Brieﬂy, the sample preparation
procedure is optimized by introducing both crude peptide fractionation
and subsequent incubation with fresh beads, while the mass spectro-
metric detection is improved by an adaptation of the duty cycle.
To reduce the complexity of the starting peptide pool we introduced
a crude fractionation into three fractions using C18 reverse-phase
chromatography and high pH elution. Basic reverse-phase fractionation
was performed in the oﬄine mode using a large Sep-Pak cartridge ﬁlled
Fig. 5. Detection of diGly peptides in SILAC labeled cells. A)
Numbers of peptides detected in the forward and reverse conditions
of the SILAC labeled HeLa cells for multiplicity settings 1 and 2, B)
Comparison of numbers of detected diGly peptides in SILAC labeled
cells in diﬀerent cell types, C) Scatterplot of diGly peptide SILAC
ratios in Bortezomib (Btz) treated HeLa cells. Only peptides that
were identiﬁed and quantiﬁed in both forward and reverse ex-
periments are shown.
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with polymeric stationary phase to allow for the fractionation of up to
40 mg of input material. The acetonitrile percentage of the ammonium
formate solution for elution into three fractions was optimized in such a
way that every fraction contained similar peptide amounts. The de-
salting step that is normally performed before the basic reverse-phase
fractionation when HPLC equipment is used can now be omitted, re-
sulting in a signiﬁcant decrease of the total time needed for the frac-
tionation to only 45 min. Since these fractions showed only a very small
overlap in peptide identiﬁcations, we decided to use these fractions for
subsequent parallel diGly peptide IPs. α-K-ε-GG Antibodies coupled to
beads were used according to the manufacturer's protocol (see
Materials and methods). Although the exact amount of antibody per
batch of beads is proprietary information, we use the same deﬁnition
for one batch in this paper as the manufacturer does in order to avoid
confusion. One batch of beads was divided into six smaller batches and
peptides were incubated with these small bead batches twice in a se-
quential manner. In normal mode top N data dependent acquisition
(DDA) analysis, N peaks from the MS1 spectrum are selected for frag-
mentation. This is done starting with the highest intensity peak, then
the second highest intense peak, etc. However, a variation to this theme
is to start with the least intense peaks and move on towards the higher
intense peaks. The rationale behind this selection procedure is that
extremely low abundant peptides will then be fragmented as well. To
obtain higher ubiquitinome coverage, the highest ﬁrst and lowest ﬁrst
peak intensity fragmentation regime runs from separate nLC-MS/MS
experiments of one sample are then combined during the data analysis
step. Altogether, this leads to a total amount of twelve nLC-MS/MS runs
per sample while making use of only one batch of antibody beads. The
improvements for each of the diﬀerent steps will now be described in
more detail.
The crude fractionation into three distinct fractions strategy reduces
the sample complexity per fraction, with comparable amounts of diGly
peptides per fraction identiﬁed (Fig. 2). The numbers of diGly peptides
that were unique in each fraction (dark blue) are high with respect to
the total number of diGly peptides in those fractions, indicating that the
quality of the peptide separation is very high. It is expected that the
diGly peptides, like the non-modiﬁed peptides from the same fraction,
in the late eluting fractions are generally more hydrophobic. Sequence
analysis of the diGly peptides for each of these fractions did not show
any bias for diGly site context motifs (Supplementary Fig. 1).
In addition, ~2500 unique diGly peptides in were identiﬁed in a
second IP incubation in addition to the ﬁrst IP incubation using the
ﬂowthrough of the ﬁrst IP with fresh antibody beads (Fig. 2). There was
no apparent diﬀerence between the ﬁrst and second IP in terms of diGly
peptide properties, such as amino acid sequence, hydrophobicity, etc.
The target speciﬁcity of this enrichment step was high, with a ratio
between the numbers of diGly peptides over the total amount of pep-
tides identiﬁed of 0.59.
Finally, the ‘least intense precursor ﬁrst’ strategy produced over four
thousand unique diGly peptides that were not detected when using the
regular DDA protocol (Fig. 2).
Of all diGly peptides identiﬁed over three biological replicate ex-
periments, 9092 were present in all of them, while almost 17,438 were
present in at least two out of three replicates (Fig. 3). Reports in the
literature on ubiquitylation proﬁling typically report around ten thou-
sand ubiquitylation sites identiﬁed in a typical experiment (e.g.,
Fig. 6. Comparison of ubiquitylation sites identiﬁed in this data set versus those collected
in the PhosphoSitePlus database.
Table 1
Gene Ontology (GO) analysis of proteins associated to up- and downregulated diGly
peptides in HeLa and U2OS cells upon proteasome inhibition by Bortezomib.
HeLa cells
Upregulated biological processes p-Value Benjamini score # proteins
Nonsense mediated decay 2.2E−38 2.37E−35 61
Translational initiation 2.5E−38 2.57E−35 65
rRNA processing 3.2E−28 2.3E−25 69
Translation 9.6E−26 5.8E−23 72
mRNA stability 9.7E−21 5.0E−18 41
APC/C catabolism 1.6E−19 7.3E−17 35
Proteasome catabolism 1.9E−19 7.5E−17 56
Cell cycle related ubiquitylation 3.9E−18 1.3E−15 32
WNT signaling 3.8E−16 9.3E−14 34
Amino acid metabolism 3.1E−15 7.5E−13 25
NF kappaB signaling 4.5E−15 1.0E−12 28
Downregulated biological processes p-Value Benjamini score # proteins
Nucleosome assembly 3.2E−26 3.9E−23 26
Translational initiation 1.5E−8 9.0E−6 13
Nonsense mediated decay 3.6E−7 8.8E−5 11
Cell-cell adhesion 2.1E−5 2.9E−3 13
Regulation of cell size 4.3E−5 5.3E−3 5
U2OS cells
Upregulated biological processes p-Value Benjamini score # proteins
Translational initiation 1.26E−48 1.55E−46 58
Nonsense mediated decay 1.11E−42 2.42E−39 50
rRNA processing 3.89E−34 8.50E−31 55
Translation 3.67E−30 8.03E−27 55
APC/C catabolism 2.85E−25 6.24E−22 31
Cell cycle related ubiquitylation 3.06E−23 6.70E−20 29
mRNA stability 1.50E−22 3.27E−19 32
Proteasome catabolism 3.64E−22 7.96E−19 42
NF kappaB signaling 1.11E−18 2.42E−15 24
WNT signaling 2.98E−17 6.52E−14 26
Amino acid metabolism 2.72E−16 4.86E−13 20
Downregulated biological processes p-Value Benjamini score # proteins
Nucleosome assembly 1.4E−24 5.3E−22 19
Microtubule-based process 6.4E−11 1.2E−8 8
Keratinocyte diﬀerentiation 1.9E−5 2.3E−3 4
Cytoskeleton organization 3.4E−5 3.1E−3 7
H3K27Me3 2.1E−4 1.3E−2 3
Table 2
Overlap of diGly peptide data sets from experiments with varying amounts of total protein
input material.
Total protein input amount # diGly peptides
Present in all analyses 4553
Detected only in 10 and 40 mg experiments 5818
Detected only in 40 mg experiment 9963
Detected only in 4 and 10 mg experiments 1233
Detected only in 4 and 40 mg experiments 1614
Detected only in 10 experiment 5896
Detected only in 4 mg experiment 1761
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[10,16]). Thus, the method described here explores the ubiquitinome in
more depth and in a reproducible manner.
For a complete list of identiﬁed diGly peptides see Supplementary
Table 1.
The amount of input material for IPs was found to inﬂuence the
ultimate number of diGly peptide identiﬁcations to a great extent. An IP
performed with 4 mg of input material produced 9803 diGly peptide
identiﬁcations, while the ratio of diGly peptide to total peptide iden-
tiﬁcation numbers was high at 0.80 (Fig. 4A). Analyses of 10 mg protein
input produced 18,427 diGly identiﬁcations, with a diGly peptide to
total peptide ratio of 0.57. These results suggest that the available
binding sites on the antibody beads may reach saturation when higher
amounts of input material are used, or that highly abundant diGly
peptides such as for instance the K48 modiﬁed tryptic peptide LIFAGK
(diGly)QLEDGR of ubiquitin mask lowly abundant diGly peptides to a
higher extent when more input material is used. Interestingly, in these
lower input samples relatively higher amounts of diGly peptide iden-
tiﬁcations were found in the least intensity peaks ﬁrst runs when
compared to the regular, i.e. highest intensity peaks ﬁrst, runs. It is
possible that the higher sample input leads to increased peak intensities
for diGly peptides, which in turn allows these peptides to be picked up
in the regular Top N analysis. This would then lead to increased de-
tection of peptides with ubiquitylation sites of low stoichiometry, but
would at the same time increase the detection of background non-diGly
peptides. When the spectral intensities of diGly peptides are plotted
with respect to their masses it is obvious that the overlapping peptides
between the analyses of diﬀerent sample input amounts are largely
peptides of relatively high intensities (Fig. 4B). Although there is quite
some overlap between the 10 mg and 40 mg analyses, almost 10,000
diGly peptides were identiﬁed exclusively in the 40 mg preparation
and> 5000 exclusively in the 10 mg preparation (Table 2). Only a
minor fraction was identiﬁed exclusively in the 4 and/or 10 mg pre-
parations and these peptides are mainly of (very) low abundance as
based on their spectral intensities. Overall, the intensity range of diGly
peptides spans almost eight orders of magnitude. It should be noted that
no replicates were taken in this experiment and it is expected that the
overlap would increase in that case.
For comparison purposes ubiquitinome analyses of untreated HeLa
cells were performed. In a duplicate experiment that includes the im-
provements described above with 10 mg total protein input 7816 diGly
peptides were identiﬁed (Supplementary Table 2). This number is a
severe reduction compared to analyses of cells treated with proteasome
inhibitors and ﬁts with earlier observations in untreated cells where
30–40% of the total number of peptides found in treated cells were
identiﬁed.
In order to illustrate the power of this improved method for ubi-
quitylation site analysis we also performed a quantitative SILAC ana-
lysis on the ubiquitinomes of Bortezomib treated HeLa cells versus non-
treated cells. Biological replicates of each sample were analyzed in a
light and heavy label swap SILAC experiment and samples were pre-
pared and analyzed as described earlier using two batches of beads for
the forward and reverse experiment. Again, of all peptides identiﬁed
over 55% were diGly peptides. The overlap of diGly peptides detected
in two independent experiments is depicted in Fig. 5A. In total, we
detected 19,481 unique diGly peptides, while 7577 of these were de-
tected in both experiments. In the quantitative analysis (SILAC settings
or multiplicity 2) relatively large diﬀerences were observed in the
numbers of diGly peptides identiﬁed exclusively in the forward condi-
tion (i.e., Bortezomib treated cells in the heavy channel, control cells in
the light channel) versus those identiﬁed exclusively in the reverse
condition (i.e., Bortezomib treated cells in the light channel, control
cells in the heavy channel): 1752 compared to 6356. We suspect that
this is due to the diﬃculties that the MaxQuant software has with the
identiﬁcation and quantitation of peptides that have measurable in-
tensities (almost) exclusively in the heavy channel accompanied by
extremely low intensities or even complete absence in the light channel.
It is expected that this phenomenon occurs at a large scale when novel
ubiquitylation sites are induced as a result of proteasome inhibition.
The ‘requantify’ option in MaxQuant apparently only partially corrects
for this. No major diﬀerences were observed between diﬀerent cell
types in terms of numbers of identiﬁed diGly peptides (Fig. 5B).
The far majority of diGly peptides are being upregulated upon
Bortezomib treatment with> 65% of the peptides having H:L ratios
of> 1.5 (Fig. 5C). Due to inhibition of the proteasome, proteins that
are sent to the proteasome for degradation will now be accumulated
instead, with proteins involved in highly active biological processes
such as cell cycle regulation and transcription being enriched. Further
GO analysis revealed an enrichment of additional cellular processes like
protein catabolism and ubiquitylation, translation and non-sense
mediated decay (Table 1). Notably, stress response proteins were highly
upregulated and we have previously shown in Drosophila that this is
because of protein biosynthesis rather than accumulation of non-de-
gradable proteins [12]. The upregulation of diGly peptides of ubiquitin
itself indicates an increase in the formation of all polyubiquitin chains
(Supplementary Table 3).
We then compared the data generated by our method to publicly
available repositories of ubiquitylation sites. The PhosphoSitePlus da-
tabase (www.phosphosite.org) was used as the reference database,
because this is one of the most extensive repositories of this kind.
Surprisingly, only 45% of the sites found in our data set overlapped
with those in the PhosphoSitePlus database, while> 20,000 of the
observed ubiquitylation sites in our data set were not covered in this
repository (Fig. 6; Supplementary Table 4). This indicates that the
method described here reaches an unprecedented depth of ubiquiti-
nome coverage.
Finally, we investigated the eﬀectiveness of this method for the
application of ubiquitylation site analysis in in vivo tissue samples. To
assess this, we extracted approx. 32 mg protein from mouse brain
tissue. It should be noted that no proteasome inhibitors or any other
methods to boost overall protein ubiquitylation were applied. Using the
experimental setup described here we identiﬁed 10,871 unique diGly
peptides in this sample (Supplementary Table 5). Given that the diGly
peptides identiﬁed here represent endogenous ubiquitylation sites with
no externally imposed imbalance because of proteasome inhibition, we
suspect that many of these ubiquitylation sites are actually signaling
events, which is in line with ideas hypothesized by others [4,19,20].
4. Conclusions
We report several improvements for a method to enrich, im-
munopurify and identify peptides with diGly remnants representing
sites of protein ubiquitylation. The numbers of identiﬁed peptides in-
dicate a depth of analysis that is to our knowledge unprecedented in the
literature. The adaptations of original procedures to analyze these
modiﬁcations include 1) fractionation of the total peptide input prior to
the speciﬁc immunoprecipitation of diGly peptides and 2) a more eﬃ-
cient decision tree in the Thermo Tune software workﬂow to optimize
the Orbitrap mass spectrometer settings for the detection of these often
extremely low abundant peptides. Furthermore, more eﬃcient wash
steps to decrease non-speciﬁc binding to the antibody beads resulted in
higher overall diGly peptide vs non-modiﬁed peptide ratios. It should
be noted here that in many reports in the literature numbers of iden-
tiﬁed diGly peptides reported are derived from accumulated analyses or
experiments. The numbers presented here represent identiﬁed diGly
peptides from a single sample and, therefore, only a single experiment.
Also, the method is suitable for the detection of high amounts of en-
dogenous ubiquitylation sites in mouse tissue samples. In conclusion,
this method is robust, reproducible and outperforms previously pub-
lished methods in terms of number of modiﬁed peptide identiﬁcations.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jprot.2017.10.014.
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